Dr Bliss Cunningham completed a PhD in 2018 from Monash University. Her PhD studies focused on the development of a passive immunotherapeutic to prevent and treat Clostridium difficile infections, supported by Immuron Ltd. This work was presented at both national and international conferences, and resulted in a co-first author publication in Scientific Reports and inclusion on a patent that has been filed in Australia, Canada, Europe, USA, China and New Zealand. She recently began working with the McDevitt group as a Junior Post-doctorate, investigating the role of transition metal ions in pneumococcal infections.
